Compare CSX Corporation (CSX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs IDEXX Laboratories, Inc. — how do they compare? CSX Corporation trades at $50.1 (market cap $92.55B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: CSX Corporation is far larger — about 2× IDEXX Laboratories, Inc.'s market cap, and CSX Corporation pays a 1.12% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| CSX | IDXX | |
|---|---|---|
Market Cap | $92.55B | $46.22B |
Sector | Industrials | Health |
52-Week High | $53.21 | $766.68 |
52-Week Low | $32.05 | $526.44 |
Enterprise Value | $110.52B | $47.12B |
Dividend Yield | 1.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $50.09, down slightly by 0.06% today, with a neutral technical signal. Recent Q2 2026 earnings beat expectations with EPS of $0.54 versus $0.518 expected, driven by 10% revenue growth and improved margins. Analyst consensus is bullish with a $52.57 price target, supported by strong cash flow trends and a 58.69% buy rating from coverage.
The outlook is positive due to volume growth and cost controls, but risks include fuel cost pressures and competitive freight markets. With a P/E of 29.05 above industry averages, the stock offers growth potential if earnings momentum continues, though high debt levels warrant monitoring.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
